Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Lonapegsomatropin (Skytrofa) in Prepubertal Children with Growth Hormone Deficiency (GHD): At 52 weeks, lonapegsomatropin demonstrated comparable efficacy in height velocity and height standard deviation score (SDS) to other long-acting growth hormones like somatrogon and somapacitan. Lonapegsomatropin (PEG-long-acting growth hormone (LAGH) (mean difference (MD): - 0.031, 95% credible interval (CrI): - 0.278, 0.215)) showed slight advantages in height velocity (MD 1.335) and height SDS compared to somatrogon and somapacitan, although results were variable with wide confidence intervals.
• Safety of Lonapegsomatropin: Lonapegsomatropin was generally well tolerated, with no significant difference in the risk of adverse events compared to somatrogon, somapacitan, or daily growth hormone (GH). Lonapegsomatropin demonstrated a slightly lower risk of adverse events compared to somatrogon (relative risk (RR) (somatrogon, RR: 1.1, 95% CrI: 0.98, 1.2; somapacitan, RR: 1.1, 95% CrI: 0.96, 1.4; lonapegsomatropin, RR, 1.1, 95% CrI: 0.91, 1.3) 1.1) and somapacitan (RR 1.1). Injection site pain was specifically noted for somatrogon in one study.
• Specific Safety Concern for Somatrogon: Injection site pain was specifically noted for somatrogon but was not highlighted for lonapegsomatropin.
• The population of focus consisted of prepubertal children with GHD, with no significant differences in effectiveness outcomes noted across specific subgroups. There were no additional findings explicitly related to subgroups based on age, gender, or comorbid conditions.